老年患者确实受益于诱导化疗:以高三尖杉酯碱为基础的高剂量米托蒽醌(「5+1」)诱导化疗方案在新诊断急性髓系白血病中的研究
单中心自2009年起连续治疗101例新诊断急性髓系白血病患者,采用「5+1」方案(第1-5天阿糖胞苷3 g/m²每日一次3小时输注,第2天米托蒽醌80 mg/m²)。中位年龄65岁(范围18-90),总缓解率(完全缓解+完全缓解伴血细胞计数未完全恢复)为76.2%(77/101),4周和8周死亡率分别为3/101(2.9%)和7/99(7%)。按年龄<60、60-69和≥70岁分层的中位总生存分别为56、31和9个月(log-rank,P=0.02)。
要点
- 「5+1」方案(阿糖胞苷3 g/m²第1-5天+米托蒽醌80 mg/m²第2天)总缓解率76.2%(77/101)。
- 4周和8周死亡率分别为2.9%(3/101)和7%(7/99)。
- 中位总生存按年龄<60、60-69、≥70岁分别为56、31、9个月(P=0.02)。
核心结论
- 以高剂量米托蒽醌为基础的化疗方案产生高完全缓解率,耐受性良好,更多患者能够接受包括干细胞移植在内的治愈性缓解后治疗。
研究设计与样本
- 单中心自2009年起连续治疗101例新诊断急性髓系白血病患者,评估「5+1」方案(第1-5天阿糖胞苷3 g/m²每日一次3小时输注,第2天米托蒽醌80 mg/m²)。
- 中位年龄65岁(范围18-90岁)。
主要发现
- 总缓解率(完全缓解+完全缓解伴血细胞计数未完全恢复)为76.2%(77/101)。
- 4周死亡率为3/101(2.9%),8周死亡率为7/99(7%)。
- 按年龄<60、60-69和≥70岁分层的中位总生存分别为56、31和9个月(log-rank,P=0.02)。
- 中危/高危风险类别患者中51.7%(45/84)接受异基因干细胞移植。
- 在该84例患者中,<60、60-69和≥70岁年龄组能够进行移植的患者比例分别为75%(18/24)、60.7%(17/28)和31.2%(10/32)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An intensive "5 + 1" regimen, which included bolus high dose cytarabine (HiDAC) at 3 g/m2 once daily over 3 hours on days 1-5 and high dose mitoxantrone (HDM) 80 mg/m2 on day 2, was evaluated in 101 consecutively treated newly diagnosed acute myeloid leukemia (AML) patients at a single center since 2009. The median age was 65 (range 18-90) years. The 4 and 8-week mortality in our cohort was 3/101 (2.9%) and 7/99 (7%), respectively. The overall response (complete remission [CR] + CRi) was 76.2% (77/101). The median overall survival (OS) stratified by age group <60, 60-69 and ≥70 years were 56, 31 and 9 months respectively (log-rank, P = 0.02). 51.7% (45/84) of patients with intermediate/adverse risk category proceeded to allogeneic stem cell transplants. Among these 84 patients, the percentage of patients able to proceed to transplant in age groups <60, 60-69, and ≥ 70 years were 75% (18/24), 60.7% (17/28), and 31.2% (10/32), respectively. In conclusion, HDM-based chemotherapy regimen produces high CR rates, is well tolerated and more patients can undergo curative postremission therapy including stem cell transplant.
引用
- Saini NY, Cerny J, Furtado VF, et al. Elderly do benefit from induction chemotherapy: High dose mitoxantrone-based ("5 + 1") induction chemotherapy regimen in newly diagnosed acute myeloid leukemia. Am J Hematol. 2018. PMID: 30417942. doi:10.1002/ajh.25347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。